Skip to main navigation Skip to search Skip to main content

Antibody-drug conjugates for the treatment of ovarian cancer

Research output: Contribution to journal › Review article › peer-review

Abstract

Introduction: Ovarian cancer typically presents at an advanced stage and while initial chemotherapy response rates are favorable, a majority of patients experience recurrence with the subsequent development of chemoresistance. Recurrent, platinum-resistant disease is associated with a very poor prognosis as treatment in this setting is often limited by systemic toxicity. Antibody-drug conjugates (ADCs) are novel therapeutic agents designed to target antigens specific to ovarian tumor cells with direct delivery of cytotoxic agents to combat recurrent, platinum-resistant disease while limiting systemic toxicity. Areas covered: The basic structure and function of ADCs will be reviewed as well as the current data on ADCs under investigation in ovarian cancer. Expert opinion: ADCs represent a promising class of targeted therapy in recurrent ovarian cancer with excellent response rates particularly when utilized as combination therapy. While mirvetuximab soravtansine is the only ADC that has been evaluated in a phase 3 trial, many other ADCs and trials are on the horizon. As the field of targeted therapy continues to evolve, continued development of target antigens and ADCs are likely to represent a key development in treatment of recurrent, platinum-resistant disease.

Original languageEnglish
Pages (from-to)875-887
Number of pages13
JournalExpert Opinion on Biological Therapy
Volume21
Issue number7
DOIs
StatePublished - 2021

Keywords

  • Antibody-drug conjugate
  • mirvetuximab soravtansine
  • ovarian cancer
  • targeted therapy

Fingerprint

Dive into the research topics of 'Antibody-drug conjugates for the treatment of ovarian cancer'. Together they form a unique fingerprint.

Cite this